BPH Global Advances Scientific Validation with TPIH Testing Agreement for Project Giddy-Up
BPH Global Ltd (ASX: BP8) has entered into a binding services agreement with Temasek Innovation Holdings Pte Ltd (TPIH) to initiate a structured efficacy testing program for its flagship “Project Giddy-Up,” marking a key step toward commercialisation of its seaweed-based men’s health supplement.
The two-stage, in-vitro cell-based testing program will evaluate biological activity across critical male vitality pathways, including erectile function, circulation, and hormone support. Key assays will assess PDE-5 inhibition, nitric oxide and cGMP signalling, and testosterone production, alongside safety validation through heavy metal testing. The program will compare two formulations, with the superior candidate advancing further development. Importantly, the agreement provides full IP ownership to BPH, with a structured timeline extending to October 2026 and defined deliverables including a final scientific report. The initiative supports the Company’s regulatory strategy targeting AUST L (TGA) listing on the ARTG, strengthening its evidence base and positioning within the nutraceutical market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
BPH Global Advances Scientific Validation with TPIH Testing Agreement for Project Giddy-Up
BPH Global Ltd (ASX: BP8) has entered into a binding services agreement with Temasek Innovation Holdings Pte Ltd (TPIH) to initiate a structured efficacy testing program for its flagship “Project Giddy-Up,” marking a key step toward commercialisation of its seaweed-based men’s health supplement.
The two-stage, in-vitro cell-based testing program will evaluate biological activity across critical male vitality pathways, including erectile function, circulation, and hormone support. Key assays will assess PDE-5 inhibition, nitric oxide and cGMP signalling, and testosterone production, alongside safety validation through heavy metal testing. The program will compare two formulations, with the superior candidate advancing further development. Importantly, the agreement provides full IP ownership to BPH, with a structured timeline extending to October 2026 and defined deliverables including a final scientific report. The initiative supports the Company’s regulatory strategy targeting AUST L (TGA) listing on the ARTG, strengthening its evidence base and positioning within the nutraceutical market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au